Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale

Annals of Internal Medicine

Volumn 137, Issue 10, 2002, Pages 834-839

  Berg, Alfred O ^a   Allan, Janet D ^a   Frame, Paul ^a   Homer, Charles J ^a   Johnson, Mark S ^a   Klein, Jonathan D ^a   Lieu, Tracy A ^a   Orleans, C Tracy ^a   Peipert, Jeffrey F ^a   Pender, Nola J ^a   Siu, Albert L ^a   Teutsch, Steven M ^a   Westhoff, Carolyn ^a   Woolf, Steven H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; SEX HORMONE;

BREAST CANCER; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEEP VEIN THROMBOSIS; DEMENTIA; ENDOMETRIUM CANCER; FEMALE; FRACTURE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; OSTEOPOROSIS; OVARY CANCER; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE; UNITED STATES;

EID: 0037137191     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-10-200211190-00013     Document Type: Review

References (31)

1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33. [PMID: 12117397]
2. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37. [PMID: 1443971]
3. Cancer Facts & Figures 2002. Special Section: Colorectal Cancer and Early Detection. American Cancer Society. Accessed 5 June 2002 at www.cancer.org/downloads/STT/cancer%20Facts%20&%20Figures% 202002%20RevCovP6P7TmPWSecured.pdf.
4. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285: 2891-7. [PMID: 11401611]
5. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:58-66. [PMID: 12090863]
6. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am J Med. 1999; 106:574-82. [PMID: 10335731]
7. Nelson H, Humphrey L, LeBlanc E, et al. Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions. Summary of the Evidence for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Available at www.ahrq.gov/clinic/serfiles.htm.
8. LeBlanc E, Chan B, Nelson H. Hormone Replacement Therapy and Cognition. Systematic Evidence Review No. 2. Oregon Health & Science Evidence-based Practice Center. Contract no. 290-97-0018. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Available at www.ahrq.gov/serfiles.htm.
9. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: The role of study design in meta-analysis. Epidemiology. 1994;5:415-21. [PMID: 7918811]
10. Humphrey LL, et al. Hormone Replacement Therapy and Breast Cancer. Systematic Evidence Review No. 14. Oregon Health & Science University Evidence-based Practice Center. Contract no. 290-97-0018. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Available at www.ahrq.gov/clinic/serfiles.htm.
11. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-93. [PMID: 7753136]
12. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127:973-80. [PMID: 9412302]
13. Humphrey LL, Takano L, Chan B. Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease. Systematic Evidence Review No. 10. Oregon Health & Science University Evidence-based Practice Center. Contract no. 290-97-0018. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Available at www.ahrq.gov/clinic/serfiles.htm.
14. Humphrey LL, Chan BK, Sox HC, Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273-84. [PMID: 12186518]
15. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638-42. [PMID: 11156873]
16. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-9. [PMID: 11680444]
17. Miller J, Chan B, Nelson H. Hormone Replacement Therapy and Risk of Venous Thromboembolism. Systematic Evidence Review No. 11, Oregon Health & Science University Evidence-based Practice Center, Contract no. 290-97-0018. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Available at www.ahrq.gov/clinic/serfiles.htm.
18. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:680-90. [PMID: 11992304]
19. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol. 1995;85:304-13. [PMID: 7824251]
20. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288:334-41. [PMID: 12117398]
21. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 2001;285:1460-5. [PMID: 11255422]
22. Petsson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - Long-term follow-up of a Swedish cohort. Int J Cancer. 1996;67:327-32. [PMID: 8707404]
23. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol. 1994;83:5-11. [PMID: 8272307]
24. Simon JA, Hunninghake DB, Agarwal SK, Lin F, Cauley JA, Ireland CC, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2001;135:493-501. [PMID: 11578152]
25. Guidelines for Women's Health Care. 2nd Ed. American College of Obstetricians and Gynecologists. Washington, DC: American Coll of Obstetricians and Gynecologists; 2002:130-3, 171-6, 314-8.
26. Report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. The North American Menopause Society. Accessed at www.menopause.org.
27. American Heart Association. Q & A About Hormone Replacement Therapy. Accessed at http://216.185.112.5/presenter.jhtml?identifier=3004068.
28. Nawaz H, Katz DL. American College of Preventive Medicine Practice Policy Statement: perimenopausal and postmenopausal hormone replacement therapy. Am J Prev Med. 1999;17:250-4. [PMID: 10987643]
29. Medical guidelines for clinical practice for management of menopause. The American Association of Clinical Endocrinologists. Endocrine Practice. 1999;5: 355-66.
30. Sadovsky R. Recent Analysis of Hormone Replacement Therapy. Accessed 5 June 2002 at www.aafp.org/afp/20000101/tips/17.html.
31. Canadian Task Force on the Periodic Health Examination. Ottawa (Canada): Health Canada; Updates available at: http://www.ctfphc.org/index.html.